Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;35(1):233-244.
doi: 10.1007/s40620-021-01068-0. Epub 2021 May 20.

Electrocardiographic parameters of left ventricular hypertrophy and prediction of mortality in hemodialysis patients

Matthias C Braunisch  1 , Peter Gundel  2   3 , Stanislas Werfel  2 , Christopher C Mayer  4 , Axel Bauer  5   6 , Bernhard Haller  7 , Roman Günthner  2 , Georg Lorenz  2 , Susanne Angermann  2 , Julia Matschkal  2 , Carolin Schaller  2 , Christopher Holzmann-Littig  2   8 , Stephan Kemmner  2   9 , Johannes Mann  10   11 , Axel Krieter  12 , Lutz Renders  2 , Siegfried Wassertheurer  4 , Georg Schmidt  13 , Uwe Heemann  2 , Marek Malik  14   15 , Christoph Schmaderer  16
Affiliations

Electrocardiographic parameters of left ventricular hypertrophy and prediction of mortality in hemodialysis patients

Matthias C Braunisch et al. J Nephrol. 2022 Jan.

Abstract

Background: In hemodialysis patients, left ventricular hypertrophy (LVH) contributes to high cardiovascular mortality. We examined cardiovascular mortality prediction by the recently proposed Peguero-Lo Presti voltage since it identifies more patients with electrocardiographic (ECG) LVH than Cornell or Sokolow-Lyon voltages.

Methods: A total of 308 patients on hemodialysis underwent 24 h ECG recordings. LVH parameters were measured before and after dialysis. The primary endpoint of cardiovascular mortality was recorded during a median 3-year follow up. Risk prediction was assessed by Cox regression, both unadjusted and adjusted for the Charlson Comorbidity Index and the Cardiovascular Mortality Risk Score.

Results: The Peguero-Lo Presti voltage identified with 21% the most patients with positive LVH criteria. All voltages significantly increased during dialysis. Factors such as ultrafiltration rate, Kt/V, body mass index, sex, and phosphate were the most relevant for these changes. During follow-up, 26 cardiovascular deaths occurred. Post-dialysis Peguero-Lo Presti cut-off as well as the Peguero-Lo Presti and Cornell voltages were independently associated with cardiovascular mortality in unadjusted and adjusted analysis. The Sokolow-Lyon voltage was not significantly associated with mortality. An optimal cut-off for the prediction of cardiovascular mortality was estimated at 1.38 mV for the Peguero-Lo Presti.

Conclusions: The post-dialysis Peguero-Lo Presti cut-off as well as the Peguero-Lo Presti and Cornell voltages allowed independent risk prediction of cardiovascular mortality in hemodialysis patients. Measuring the ECG LVH parameters after dialysis might allow a standardized interpretation as dialysis-specific factors influence the voltages.

Keywords: Cardiovascular mortality; Hemodialysis; Left ventricular hypertrophy; Peguero-Lo presti.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest. Matthias Christoph Braunisch reports received personal fees from Vifor Pharma unrelated to the project.

Figures

Fig. 1
Fig. 1
Flow-chart of participants. Abbreviations: CV cardiovascular; ECG electrocardiogram; LBBB left bundle branch block; RBBB right bundle branch block
Fig. 2
Fig. 2
Changes in pre- to post-dialysis voltages. A–C show Bland–Altman plots for the agreement of pre- and post-dialysis voltages. The black line depicts the mean difference between the two measurements, the dotted lines depict the limits of agreement (mean delta − 1.96 × standard deviation to mean delta + 1.96 × standard deviation). The blue dotted line describes the regression line. D–F show the changes in voltage cut-offs from pre- to post-dialysis which were compared using the McNemar test
Fig. 3
Fig. 3
Area-proportional Euler diagrams of positive ECG LVH voltage criteria measured after dialysis. Peguero-Lo Presti (n = 59): ≥ 2.3 mV (women), ≥ 2.8 (men); Cornell (n = 24): > 2.0 mV (women), > 2.8 mV (men); Sokolow-Lyon (n = 16): ≥ 3.5 mV
Fig. 4
Fig. 4
Cumulative cardiovascular mortality curves stratified by post-dialysis A Peguero-Lo Presti, B Cornell, and C Sokolow-Lyon cut-offs. Hazard ratio after adjustment for the Charlson Comorbidity Index and the Cardiovascular Mortality Risk Score. Abbreviations: CI confidence interval; HR hazard ratio; NA not applicable since there were no mortality events in the positive group
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(5 Suppl 3):S112–119. doi: 10.1053/ajkd.1998.v32.pm9820470. - DOI - PubMed
    1. Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis. 2005;46(2):320–327. doi: 10.1053/j.ajkd.2005.04.031. - DOI - PubMed
    1. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47(1):186–192. doi: 10.1038/ki.1995.22. - DOI - PubMed
    1. Hickson LJ, Negrotto SM, Onuigbo M, Scott CG, Rule AD, Norby SM, Albright RC, Casey ET, Dillon JJ, Pellikka PA, Pislaru SV, Best PJM, Villarraga HR, Lin G, Williams AW, Nkomo VT. Echocardiography criteria for structural heart disease in patients with end-stage renal disease initiating hemodialysis. J Am Coll Cardiol. 2016;67(10):1173–1182. doi: 10.1016/j.jacc.2015.12.052. - DOI - PMC - PubMed
    1. Ozkahya M, Ok E, Cirit M, Aydin S, Akçiçek F, Başçi A, Dorhout Mees EJ. Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol Dial Transplant. 1998;13(6):1489–1493. doi: 10.1093/ndt/13.6.1489. - DOI - PubMed

LinkOut - more resources